

Prosena explain Exon Skipping in Duchenne Muscular Dystrophy at 6th annual RNA Therapeutics Summit

RNA Therapeutics, 16th & 17th February, London UK

LONDON, LONDON, UNITED KINGDOM, November 27, 2014 /EINPresswire.com/ -- It was announced earlier this week that US Drug maker BioMarin will acquire biopharmaceutical company Prosensa, for a total of \$680 million. The deal includes two additional payments of roughly \$80 million, tied to regulatory approvals of a Duchenne drug currently being developed by Prosensa.

Prosensa is one of a few companies developing treatments for the progressive muscle-wasting disorder, Duchenne and is advancing an RNA-based treatment that targets an abnormality in part of the dystrophin gene. Both the Prosensa and Sarepta Therapeutics target abnormalities in exon 51, which affects 13 percent of patients with Duchenne.*



Hear more from both Prosensa and Serepta Therapeutics at SMI's 6th annual conference on [RNA Therapeutics](http://www.therapeutics-rna.com), when it returns to London on 16th & 17th February 2015.

Prosensa Chief Medical Officer and SVP of R&D, Giles Campion, will be providing attendees with unique insights in a presentation entitled: Exon Skipping in Duchenne Muscular Dystrophy. The address will deliver learnings from a global clinical programme, discuss splice switching and offer guidance on accelerating regulatory paths to approval. He will then go onto leading a round table discussion on developing RNA Therapeutics for rare diseases.

A keynote address from Sarepta entitled: From RNA splicing to Eteplirsen trials - a drug for Duchenne muscular dystrophy, will be presented by Distinguished Scientist, Ryszard Kole. Sarepta Therapeutics will present their findings from a 120 day week trial, discuss the invention of RNA splicing and provide insight into Eteplirsen induced exon skipping of 51 in dystrophin pre-mRNA in DMD patients.

Further details are available online at www.therapeutics-rna.com

RNA Therapeutics: From Cell to Sales – Clearing the Path to Market

16-17 February 2015

Marriott Regents Park Hotel, London UK

www.therapeutics-rna.com

--- end ---

Source: <http://www.xconomy.com/san-francisco/2014/11/24/biomarin-gambles-840m-on-prosensas-duchenne-drug/>

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/236877101>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.